---
document_datetime: 2025-12-29 08:13:52
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/gefzuris.html
document_name: gefzuris.html
version: success
processing_time: 0.040225
conversion_datetime: 2025-12-30 01:12:08.643452
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Gefzuris

[RSS](/en/individual-human-medicine.xml/67703)

##### Application withdrawn

The application for this medicine has been withdrawn

gefapixant Medicine Human Application withdrawn

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Key facts](#key-facts)
- [All documents](#all-documents)
- [Related information on withdrawals](#related-info-withdrawn)
- [News on Gefzuris](#news-on)

- Application under evaluation
- Withdrawal of application

## Overview

The applicant withdrew the marketing authorisation application for Gefzuris (gefapixant) on 14 July 2023. It was a duplicate of the application for another medicine, Lyfnua, which EMA's human medicines committee (CHMP) was evaluating in parallel, and which is not affected by this withdrawal.

Further details are included in the withdrawal letter.

## Key facts

Name of medicine Gefzuris Active substance gefapixant International non-proprietary name (INN) or common name gefapixant Therapeutic area (MeSH) Cough Anatomical therapeutic chemical (ATC) code R05DB29 EMA product number EMEA/H/C/005884 Marketing authorisation applicant Merck Sharp &amp; Dohme B.V. Withdrawal of application 14/07/2023

## All documents

Withdrawal assessment report for Gefzuris

Adopted

Reference Number: EMA/357359/2023

English (EN) (5.99 MB - PDF)

**First published:** 08/11/2023

[View](/en/documents/withdrawal-report/withdrawal-assessment-report-gefzuris_en.pdf)

Withdrawal letter: Gefzuris

English (EN) (8.42 KB - PDF)

**First published:** 21/07/2023

[View](/en/documents/withdrawal-letter/withdrawal-letter-gefzuris_en.pdf)

#### Related information on withdrawals

A question-and-answer (Q&amp;A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.

An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').

#### News on Gefzuris

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 July 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-july-2023) 21/07/2023

**This page was last updated on** 08/11/2023

## Share this page

[Back to top](#main-content)